Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) – Equities research analysts at Wedbush issued their Q2 2023 EPS estimates for Imago BioSciences in a research report issued to clients and investors on Monday, November 21st. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($0.63) per share for the quarter. Wedbush currently has a “Neutral” rating and a $36.00 target price on the stock. The consensus estimate for Imago BioSciences’ current full-year earnings is ($1.93) per share. Wedbush also issued estimates for Imago BioSciences’ Q3 2023 earnings at ($0.61) EPS and Q4 2023 earnings at ($0.65) EPS.
A number of other brokerages have also recently issued reports on IMGO. Jefferies Financial Group cut shares of Imago BioSciences from a “buy” rating to a “hold” rating and boosted their target price for the company from $35.00 to $36.00 in a research report on Monday. Cowen downgraded Imago BioSciences to a “market perform” rating and set a $36.00 price target for the company. in a research note on Tuesday. Cowen downgraded Imago BioSciences from an “outperform” rating to a “market perform” rating and set a $36.00 price target for the company. in a research note on Monday. HC Wainwright downgraded Imago BioSciences from a “buy” rating to a “neutral” rating and boosted their price target for the company from $35.00 to $36.00 in a research note on Tuesday. Finally, Guggenheim set a $36.00 price target on Imago BioSciences in a research note on Thursday. Five analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.00.
Imago BioSciences Stock Performance
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY acquired a new position in Imago BioSciences during the first quarter worth about $28,000. Ameritas Investment Partners Inc. raised its stake in Imago BioSciences by 108.3% during the first quarter. Ameritas Investment Partners Inc. now owns 1,556 shares of the company’s stock worth $30,000 after acquiring an additional 809 shares in the last quarter. Amalgamated Bank acquired a new position in Imago BioSciences during the first quarter worth about $41,000. Legal & General Group Plc raised its stake in Imago BioSciences by 46.2% during the second quarter. Legal & General Group Plc now owns 6,098 shares of the company’s stock worth $81,000 after acquiring an additional 1,926 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Imago BioSciences by 305.1% during the third quarter. Tower Research Capital LLC TRC now owns 5,643 shares of the company’s stock worth $85,000 after acquiring an additional 4,250 shares in the last quarter. Institutional investors and hedge funds own 99.50% of the company’s stock.
Imago BioSciences Company Profile
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.